Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex establishes joint venture for OvaRex

July 6, 2000

Antigenics commences first phase III trial of its Oncophage cancer vaccine

July 6, 2000

Biomira acquires remaining rights to Theratope from Chiron

July 4, 2000

Cancer immunotherapies based on WT-1 and gata-1 peptide epitopes

July 4, 2000

Cel-Sci receives permission to start phase II cancer trial in Canada

June 30, 2000

StressGen's HspE7 advances to phase III trials in anal dysplasia

June 28, 2000

FDA completes initial review of BLA for Campath

June 28, 2000

Lorus Therapeutics reports strong meta-analysis results for Virulizin, prepares for phase III trials

June 28, 2000

Tumor-associated antigen-derived immunogenic polypeptides useful for cancer immunotherapy

June 23, 2000

Mylotarg now available in U.S. as treatment for relapsed AML

June 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...